Donate

Baxter Reports Success in Long-Acting Hemophilia Product

August 23, 2014

This article was originally published in Reuters on August 21, 2014. Click here to read it in its entirety. ______________________ Baxter International Inc said a more potent version of its flagship blood disorder drug Advate met the main goal in a late-stage study. The experimental drug, BAX 855, was being tested as a preventive therapy […]


Sign up for E-mails, Dateline Magazine, and other ways to stay connected.